Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 15/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691714 | 0.89 | FYN (0.39) | DYRK3CCNA2CDK2CDK5DYRK1A | |
| SCHEMBL2946667 | 0.89 | FYN (0.50) | FYN | |
| SCHEMBL20486254 | 0.83 | NTRK1 (0.41) | FYN | |
| SCHEMBL2948461 | 0.82 | FYN (0.53) | FYN | |
| SCHEMBL2951390 | 0.82 | FYN (0.54) | DYRK3CCNA2CDK2CDK5DYRK1A | |
| SCHEMBL1053479 | 0.81 | FYN (0.56) | FYN | |
| SCHEMBL2948418 | 0.81 | FYN (0.57) | DYRK3CCNA2CDK2DYRK1ADYRK2 | |
| SCHEMBL18613617 | 0.81 | FYN (0.58) | FYN | |
| SCHEMBL2947614 | 0.81 | FYN (0.54) | DYRK3CCNA2CDK2CDK5DYRK1A | |
| SCHEMBL18613580 | 0.80 | FYN (0.61) | FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | claimed |
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| EP-1900739-A1 | Diazolodiazine derivatives as kinase inhibitors | CELLZOME AG (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008025822-A1 | DIAZOLODIAZINE DERIVATIVES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2008-03-06 | — | — | WO | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | DYRK3 539/4885CCNA2 650/4885CDK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.